Last updated on December 2018

Migraine Headaches

Brief description of study

Dihydroergotamine mesylate (DHE) is an acute migraine medication that is currently available in the United States for administration as an injection or by a nasal spray applicator. INP104 is the name of the experimental product being used in this study. INP104 is a combination of DHE and a type of nasal spray device called the Olfactory Precision Deliver (POD) device. The study sponsor is developing this product to deliver DHE to the upper nasal cavity.


Clinical Study Identifier: TX209385

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.